(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 27 May 2004 (27.05.2004)

(10) International Publication Number WO 2004/044135 A3

- (51) International Patent Classification⁷: C07H 21/02. 21/04, C12N 15/85, 15/86, A61K 48/00, C12P 19/34,
- C12Q 01/68
- (21) International Application Number:

PCT/US2003/035068

(22) International Filing Date:

4 November 2003 (04.11.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

US 60/423.760 5 November 2002 (05.11.2002) 10/660,059 11 September 2003 (11.09.2003)

- (71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ECKER, David, J. [US/US]; 1041 Saxony Road, Encinitas, CA 92024 (US). BOSWELL, Herb [US/US]; 977 Hawthorne Court, San Marcos, CA 92069 (US). CROOKE, Stanley, T. [US/US]; 3211 Piragua Street, Carlsbad, CA 92009 (US).

- (74) Agents: CALDWELL, John, W. et al.; Woodcock Washburn LLP, One Liberty Place - 46th Floor, Philadelphia, PA 19103 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GII, GM, IIR, IIU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GII, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report:

13 January 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STRUCTURAL MOTIFS AND OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION

(57) Abstract: Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers has a non-linear secondary structure or is part of a multiple oligomer assembly. Oligonucleotide/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein the oligomer has has a non-linear secondary structure or is part of a multiple oligomer assembly.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/35068

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C07H 21/02, 21/04; C12N 15/85, 15/86; A61K 48/00; C12P 19/34; C12Q 01/68					
US CL : 435/6, 91.1, 325, 375; 536/24.3, 24.5; 514/44					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/6, 91.1, 325, 375; 536/24.3, 24.5; 514/44					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN, medline, caplus, lifesci, embase, uspatfull, biosis					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where a	ppropriate,	of the relevant passages	Relevant to claim No.	
Y V	VO 94/23026 A1 (GENSET) 13 October 1994 (10	13.94), see	e entire document.	1-83	
b	ZHOU ET AL. Post-transcriptional suppression of gene expression in Xenopus embryos by small interfering RNA. Nucleic Acids Research. February 2002, Vol. 30, No. 7, pages 1664-1669, see entire document.				
	WO 01/29058 A1 (UNIVERSITY OF MASSACHUSETTS) 26 April 2001 (26.04.01), see entire document.				
			,	,	
Further documents are listed in the continuation of Box C. See patent family annex.					
* Special categories of cited documents:			later document published after the inter		
"A" document defining the general state of the art which is not considered to be of particular relevance			principle or theory underlying the inven		
"E" earlier application or patent published on or after the international filing date		"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"Y"	considered to involve an inventive step when the document is		
"O" document refe	document referring to an oral disclosure, use, exhibition or other means		combined with one or more other such being obvious to a person skilled in the		
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent family			
Date of the actual completion of the international search 17 March 2004 (17.03.2004)		Dat of mailing of the international search report			
			of officer	1	
Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Karen A. Lacouroter Bell-Harrisfu			
P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 872-9306		Telephone No. (571) 272-1600			
	. 55, 5.2 7000			_	